二甲双胍、格列齐特缓释片和罗格列酮单药治疗及联合治疗2型糖尿病的比较
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
作者信息
Vilar Lucio, Canadas Viviane, Arruda Maria Juliana, Arahata Carla, Agra Rodrigo, Pontes Lisete, Montenegro Larissa, Vilar Clarice Freitas, Silva Lidiane Moura e, Albuquerque José Luciano, Gusmão Amaro
机构信息
Centro de Diabetes e Endocrinologia de Pernambuco, Recife, PE, Brasil.
出版信息
Arq Bras Endocrinol Metabol. 2010 Mar;54(3):311-8. doi: 10.1590/s0004-27302010000300010.
OBJECTIVE
To compare the efficacy and tolerability of metformin, rosiglitazone and gliclazide MR as monotherapy and in combination in the treatment of type 2 diabetes.
SUBJECTS AND METHODS
250 patients treated with oral antidiabetic agents for at least 24 weeks in monotherapy or in combination therapy were included in this retrospective study.
RESULTS
As monotherapy the reduction of fasting plasma glucose (FPG), postprandial glycemia (PPG) and HbA1c was similar with the three drugs after 24 weeks. Among patients on combination therapy, the reduction in HbA1c, FPG and PPG was significantly lower with rosiglitazone plus metformin, as compared to metformin plus gliclazide MR or gliclazide MR plus rosiglitazone. Patients treated with rosiglitazone achieved less favorable changes in lipid profile.
CONCLUSION
In monotherapy all drugs were equally effective in improving glycemic control, whereas the combination of metformin plus gliclazide MR provided the best results concerning the improvement of both, glycemic control and lipid profile.
目的
比较二甲双胍、罗格列酮和格列齐特缓释片单药治疗及联合治疗2型糖尿病的疗效和耐受性。
受试者与方法
本回顾性研究纳入了250例接受口服降糖药单药治疗或联合治疗至少24周的患者。
结果
单药治疗24周后，三种药物降低空腹血糖（FPG）、餐后血糖（PPG）和糖化血红蛋白（HbA1c）的效果相似。在联合治疗的患者中，与二甲双胍加格列齐特缓释片或格列齐特缓释片加罗格列酮相比，罗格列酮加二甲双胍降低HbA1c、FPG和PPG的幅度显著更低。接受罗格列酮治疗的患者血脂谱变化不太理想。
结论
单药治疗时，所有药物在改善血糖控制方面效果相当，而二甲双胍加格列齐特缓释片联合治疗在改善血糖控制和血脂谱方面效果最佳。
Zotero 插件